The BRAF V600E mutation is reported in half of patients with Langerhans cell histiocytosis (LCH). This study investigated the detection of the BRAF V600E allele in circulating cell-free (ccf) DNA in a paediatric LCH cohort. Children with BRAF V600E -mutated LCH were investigated to detect ccf BRAF V600E at diagnosis (n = 48) and during follow-up (n = 17) using a picolitre-droplet digital PCR assay. At diagnosis, ccf BRAF V600E was positive in 15/15 (100%) patients with risk-organ positive multisystem (RO+ MS) LCH, 5/12 (42%) of patients with ROÀ MS LCH and 3/21 (14%) patients with single-system (SS) LCH (P < 0Á001, Fisher's exact test). The positive BRAF V600E load was higher for RO+ patients (mean, 2Á90%; range, 0Á04-11Á4%) than for ROÀ patients (mean, 0Á16%; range, 0Á01-0Á39) (P = 0Á003, Mann-Whitney U test). After first-line vinblastine-steroid induction therapy, 7/7 (100%) of the non-responders remained positive for ccf BRAF V600E compared to 2/4 (50%) of the partial-responders and 0/4 of the complete responders (P = 0Á002, Fisher's exact test). Six children treated with vemurafenib showed a clinical response that was associated with a decrease in the ccf BRAF V600E load at day 15. Thus, ccf BRAF V600E is a promising biomarker for monitoring the response to therapy for children with RO+ MS LCH or ROÀ LCH resistant to first-line chemotherapy.
Summary
The BRAF V600E mutation is reported in half of patients with Langerhans cell histiocytosis (LCH). This study investigated the detection of the BRAF V600E allele in circulating cell-free (ccf) DNA in a paediatric LCH cohort. Children with BRAF V600E -mutated LCH were investigated to detect ccf BRAF V600E at diagnosis (n = 48) and during follow-up (n = 17) using a picolitre-droplet digital PCR assay. At diagnosis, ccf BRAF V600E was positive in 15/15 (100%) patients with risk-organ positive multisystem (RO+ MS) LCH, 5/12 (42%) of patients with ROÀ MS LCH and 3/21 (14%) patients with single-system (SS) LCH (P < 0Á001, Fisher's exact test). The positive BRAF V600E load was higher for RO+ patients (mean, 2Á90%; range, 0Á04-11Á4%) than for ROÀ patients (mean, 0Á16%; range, 0Á01-0Á39) (P = 0Á003, Mann-Whitney U test). After first-line vinblastine-steroid induction therapy, 7/7 (100%) of the non-responders remained positive for ccf BRAF V600E compared to 2/4 (50%) of the partial-responders and 0/4 of Langerhans cell histiocytosis (LCH) is the most common histiocytosis, and is characterized by inflammatory lesions containing abundant CD1a + CD207 + histiocytes that lead to the destruction of affected tissues. This disease most commonly affects children (Egeler et al, 2010; Haupt et al, 2013) . The clinical behaviour of LCH is remarkably heterogeneous: some cases are limited, indolent and self-regressive, whereas others recur sequentially, are refractory to conventional therapy and exhibit systemic, sometimes life-threatening, multi-organ involvement. Since 2010 (Badalian-Very et al, 2010), 38-64% of all LCH cases have been reported to harbour the BRAF V600E activating mutation, and we recently reported that in a large cohort of children with LCH, the BRAF V600E status is associated with more severe clinical presentation and with increased resistance to first-line chemotherapy (H eritier et al, 2016) . In patients with solid tumours, circulating cell-free DNA (ccfDNA) in the peripheral blood contains cancer-derived DNA (Butt & Swaminathan, 2008) , and has been used as a non-invasive diagnostic procedure (liquid biopsy) (Schwarzenbach et al, 2011; Jovelet et al, 2016) . It was recently reported that BRAF V600E can be detected in ccfDNA from patients with malignancies such as colorectal cancer (Thierry et al, 2014) . Other studies have reported that such biomarkers can be used for patient management and cancer disease assessment during therapy (Jung et al, 2010; Dawson et al, 2013) . Two studies have reported the feasibility of this detection approach in an adult cohort of patients with histiocytic disorders (Kobayashi & Tojo, 2014; Hyman et al, 2015) . It could be challenging to use ccfDNA to identify the BRAF V600E mutation at diagnosis and during follow-up in order to investigate its prognosis value and whether it can be used to monitor therapy response. Few studies have used this detection strategy to detect quantitative variations in the BRAF V600E mutation burden during disease treatment, especially in children with LCH. It remains unclear whether the wide spectrum of the disease and the limitations of quantitative ccfDNA analysis affect the suitability of this strategy for this purpose. Accordingly, we conducted this study to try to determine which patients might benefit from the determination of the BRAF V600E mutation burden at diagnosis and during follow-up.
Methods

Patients
A total of 48 children (<18 years old at diagnosis) with BRAF
V600E
-mutated LCH were included in this French multicentre study. Five wild-type BRAF (BRAF WT ) LCH patients were also included as controls. The LCH BRAF status was available for all patients and was obtained from DNA from LCH lesions as described previously (H eritier et al, 2016) . Demographic data, type of treatment, clinical characteristics, and the extent of disease were recorded according to the classification system established by the International LCH Study Group criteria (Haupt et al, 2013) . Patients were classified according to the number of organs or systems involved and risk organ (RO) involvement. The relevant ROs were liver, spleen and the haematological system. The three classifications were single system (SS) involvement, i.e. one organ and no RO involvement; multiple system (MS) involvement but no RO involvement (ROÀ); and MS involvement and involvement of at least one RO (RO+). The disease extent was evaluated at the time of initial diagnosis and at the time of maximal disease in instances of reactivation. Follow-up data were prospectively recorded according to previously described methodologies (Guyot-Goubin et al, 2008; Rigaud et al, 2016) . Permanent consequences (PC) were defined as any irreversible clinical condition that developed at any time during the course of the disease that could be directly attributed to the natural history of LCH or its treatment (Gadner et al, 2008) . The Disease Activity Score (DAS) (Donadieu et al, 2004 ) is a quantitative score based on clinical and biological evaluations that was used to determine disease severity for each patient.
Reactivation was defined as the reappearance of signs and symptoms of active disease after either complete disease resolution or after a period of disease control that persisted for >3 months on maintenance therapy. Treatment efficacy was evaluated according to the classification system used by the International LCH Study Group criteria (Gadner et al, 2008 (Gadner et al, , 2013 . The categories were non-active disease (NAD), defined as complete resolution; active disease better (ADB) (continuous regression of disease); and non-responders (NR), who are patients with unchanged or progressive disease.
This study was approved by the Ile de France III ethics committee (#2011-A00447-34), and it was conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained for all subjects.
Sample preparation and Picolitre digital polymerase chain reaction (dPCR) For all samples, 5 ml of blood were collected, then stored at À80°C after appropriate centrifugation and finally centralized for ccfDNA extraction using the QIAmp Circulating Nucleic Acid Kit (Qiagen, Venlo, the Netherlands).
Picolitre ll. An average of 60 ng of DNA was used in each assay. Five million highly monodispersed droplets were generated using the RainDrop Source instrument following the manufacturer's instructions. The emulsions were subjected to thermocycling, starting with 2 min at 50°C, 10 min at 95°C, followed by 45 cycles of the following: 95°C, 15 s and 60°C, 1 min (using a 0Á6°C/min ramp rate). After completion, the end-point fluorescence signals from each droplet were measured using the RainDrop Sense instrument. Data analyses were performed using the RainDrop Analyst software as described previously (Taly et al, 2013) . In addition to the control samples from BRAF WT LCH children, DNA controls were used to check the specificity of the dPCR designed to detect BRAF V600E . We used sheared genomic DNA from the HT29 cell line (heterozygous for BRAF V600E )
as positive controls and negative controls were obtained from sheared wild-type genomic DNA (Human Genomic DNA, Promega, Fitchburg, WI, USA). As described previously (Taly et al, 2013) , the limit of detection of our assay is based on the limit of blank (LOB), which is defined by the frequency of the positive droplets measured in the negative controls. Based on these controls, the number of false-positive droplet events (i.e. the LOB) for the c.1799T>A (p.V600E) BRAF assay was 3.
The sensitivity of droplet-based dPCR is limited mainly by the number of molecules that can be amplified. To take in account the fact that the total BRAF allele detection count was highly variable for the different tested samples, we calculated a threshold of sensitivity for each test (i.e., defined as the highest sensitivity that could be reached for this specific sample). This threshold was calculated as the ratio of the positive droplet event just over the LOB (which was invariably 4) to the number of total BRAF allele detection count for the considered assay. This threshold was specified for all negative results in this study.
For negative samples, if the total BRAF allele detection count was lower than 500, the assay reaction was considered non-informative because of a lack of sensitivity (threshold of sensitivity estimated to be higher than 8 9 10 À3 ), and the sample was subjected to a new assay. Similarly, for samples presenting ambiguous results (i.e. presenting droplet clusters with very few droplets close to the LOB or non-clustered populations of droplets) a new test was performed to confirm or exclude positivity (involving more DNA in cases where the number of droplets was close to LOB).
Statistical analysis
Differences between groups were tested with the MannWhitney U test for quantitative variables and with Fisher's exact test for qualitative variables. Survival analyses included the interval between diagnosis and an event (reactivation or death) or the last examination. Survival rates were estimated using the Kaplan-Meier method, and subgroups were compared using the log-rank test. All statistical analyses were performed with STATA 13 software (STATA, College Station, TX; Computing Resource Center, Santa Monica, CA). The cut-off date for these analyses was 30 September 2016. For variation analysis of the quantitative BRAF V600E load between samples, when the detection was negative at a specified threshold of sensitivity for a sample, the considered BRAF V600E load value for this sample was the specified threshold of sensitivity.
Results
Samples at diagnosis were obtained from 48 BRAF V600E -mutated LCH patients and 5 BRAF WT -LCH control patients.
Among them, sequential samples during follow-up were available for 17 BRAF V600E -mutated LCH patients (Fig 1) .
The characteristics of the studied BRAF V600E -mutated LCH patients are summarized in Table I . At diagnosis, 21 patients were SS, 12 were ROÀ MS and 15 were RO+ MS. The median age at diagnosis was 2Á1 years, and the mean DAS score was 4Á4. The median follow-up of this cohort was 2Á2 years (range, 0Á4-11Á7), and the 5-year recurrence rate (Fig 2A) . The sensitivity range of detection was not significantly different in the SS, ROÀ MS, and RO+ MS subgroups (P = 0Á779, Fisher's exact test). Positive BRAF V600E load was significantly higher for the 15 RO+ children (mean, 2Á90%; range, 0Á04-11Á4%) than for the 8 ROÀ children (mean, 0Á16%; range, 0Á01-0Á39) (P = 0Á003, Mann-Whitney U test). According to the prognostic DAS score, 100% of children with DAS ≥ 7 were positive for BRAF V600E detection, compared to 66Á7% and 18Á5% of patients with DAS values between 3 and 6, and DAS values below 3, respectively (P < 0Á001, Fisher's exact test) (Fig 2B) .
Among the 21 SS LCH children that were studied, 11 had unifocal bone LCH, 6 had multifocal bone LCH, 3 had multifocal skin LCH and one patient had the thymus as the sole involvement. The BRAF V600E allele loads for the 3/21 positive SS LCH children were very similar (0Á17%, 0Á18%, and 0Á27%), but the children had different clinical presentations: one child had unifocal bone LCH, one child had multifocal bone LCH, and one child had multifocal skin LCH. The latter child had a recurrence diagnosed 4 months after the initial diagnosis, with new bone localization that was undetectable at the first baseline evaluation. The 12 studied ROÀ MS LCH children included 7 cases with bone-associated skin LCH, one case with bone-associated lung LCH and 4 cases with pituitary involvement that was associated with bone involvement in 3 cases and with skin involvement in one case. For 5/12 children with ccf BRAF V600E -positive ROÀ MS LCH, the BRAF V600E allele load ranged from 0Á01% to 0Á39%, which is close to the threshold of sensitivity; 4 cases had bone-associated skin LCH and one case had a pituitary-associated bone LCH. The 15 RO+ MS LCH cases were all young children who had a median age at diagnosis of 0Á9 years (range, 0Á2-2Á8). All except one of these children presented with severe active diffuse MS LCH with RO involvement. The only case with mild active disease presented with sclerosing cholangitis that was associated with long-lasting mild skin condition that was undiagnosed for 18 months. This child was the only MS RO+ child for whom the ccfDNA BRAF V600E detection positivity at diagnosis was below 0Á1% (it was 0Á04%). A total of 84% of the negative samples reached the 10
À3
threshold of sensitivity determined according to the number of total BRAF allele detection count for each sample. The clinical characteristics and outcomes of the 19 children with positive ccf BRAF V600E detection ≥10 À3 at diagnosis were compared to the 25 children with a negative BRAF V600E detection according to this threshold (Table II) . Of the patients with positivity ≥10 À3 , 73Á7% had a RO+ MS LCH, 10Á5% had a ROÀ MS LCH, and 15Á8% had a SS LCH (P < 0Á001, Fisher's exact test). Young age at diagnosis and RO+ involvement (liver, spleen, haematological) were also associated with positivity ≥10 À3 . Although patients with positive detection ≥10 À3 showed a tendency to have a higher LCH reactivation risk than those with <10 À3 (2-year reactivation rate, 48Á1% and 32Á3%, respectively; P = 0Á07, log-rank test; Fig 3) , positive detection status at diagnosis was not associated with permanent consequences (26Á3 and 36Á0%, respectively; P = 0Á53).
The value of circulating cell-free BRAF V600E detection during follow-up Seventeen LCH children had multiple samples that were available for ccf BRAF V600E quantification during follow-up (Table III) . The BRAF V600E allele load (the percentage of mutant alleles relative to the total number of alleles) is shown for each patient according to the patient's clinical classification at diagnosis. Detection was positive for 14% of children with SS LCH, 42% with MS ROÀ LCH, and 100% with MS RO+ LCH (P < 0Á001, Fisher's exact test). The median BRAF V600E allele load (green line) was 0 for both SS and MS ROÀ LCH children and 1Á07% for MS RO+ children. The sensitivity range is specified for each subgroup of patients. (B) The percentages of children with positive BRAF V600E allele detection are represented according to the three DAS ranges (≤2, 3-6, and ≥7). These cut-off values are from previously published data that correlated DAS with LCH prognosis (Donadieu et al, 2004) . The P-values in each panel were calculated using Fisher's exact test. **P < 0Á001. DAS, disease activity score; LCH, Langerhans cell histiocytosis; MS, multi-system; RO, risk organ; SS, single system. who achieved a clinical response after vinblastine-steroid induction therapy (NAD, n = 2; ADB, n = 2), 2 had an evaluable sample at the end of the induction (Patients 2 and 3). Both samples were negative (reductions of more than 0Á1 log 10 and 1Á3 log 10 , respectively) and samples from the children remained negative during maintenance therapy without reactivation. The 2 other children showed reactivation and were positive for ccf BRAF V600E : 2Á9% for a child with RO+ MS LCH reactivation (Patient 6), and 0Á03% for a child with ROÀ MS LCH reactivation (Patient 7). The only child with ROÀ LCH who was a non-responder to vinblastine-steroid induction therapy (Patient 4) remained positive for ccf BRAF V600E after vinblastine-steroid induction therapy at 0Á05% (0Á53 log 10 reduction) and experienced a bone recurrence 4 months after the beginning of vinblastinesteroid maintenance therapy plus local mechlorethamine therapy. At the time of relapse, the ccf BRAF V600E level was 0Á19%. For the extent of disease [multiple system (MS); risk organ involvement (RO+); no risk organ involvement (ROÀ); single system (SS)], the significance was based on comparisons between the all three categories. LCH, Langerhans cell histiocytosis. As multi-tests were performed, P < 0Á0025 (*) was considered statistically significant. after vinblastine-steroid induction therapy (ADB n = 3, Patients 9, 10, 17), ccf BRAF V600E remained positive after induction therapy for 2 of the children (1Á25% and 0Á07% for Patients 9 and 10, respectively), and became negative for one case (Patient 17). All of the 6 non-responders to vinblastine-steroid induction therapy had persistent positive ccf BRAF V600E detection after induction therapy (median level, 3Á25%) and were managed with a second-line therapy. Patient 12 was a responder to cladribine/cytarabine combined chemotherapy (Donadieu et al, 2015) and was negative for BRAF V600E 2 months after beginning this second-line therapy (a reduction of more than 1Á86 log 10 ). Finally, 4 non-responders to vinblastine-steroid induction therapy (Patients 13, 14, 15, 16) were managed with vemurafenib therapy.
Follow-up of RO+ LCH children after diagnosis (n = 9). Of the 3 RO+ MS LCH children who achieved clinical responses
Circulating cell-free BRAF V600E kinetics according to clinical response and outcome. A total of 15/17 children who were treated by first-line vinblastine/steroid induction therapy were evaluated for ccf BRAF V600E after completing the course of induction therapy. There was positive ccf BRAF V600E detection in 0% (0/4) of the NAD responders, in 50% (2/4) of the ADB responders and in 100% (7/7) of the nonresponders (P = 0Á002, Fisher's exact test). The mean level of ccf BRAF V600E in the children with positive detection was 0Á66% for ADB responders (range, 0Á07-1Á25%) and 5Á37% for non-responders (range, 0Á05-17Á6%) (P = 0Á24, MannWhitney U test). Six children with severe active diffuse RO+ MS LCH and detectable ccf BRAF V600E were treated with vemurafenib, and all 6 had a clinical response. All cases showed a concomitant decrease in the ccf BRAF V600E load on day 15 (mean reduction, 0Á91 log 10 ; range 0Á10-1Á71). For the 3 children for whom vemurafenib therapy was stopped, recurrence occurred and ccf BRAF V600E was positive at recurrence for 2/2 tested samples (0Á61% for Patient 8 and 20Á5% for Patient 15). Finally, 5 children were investigated after therapy discontinuation with NAD status, and all were negative for ccf BRAF
V600E
.
Discussion
We reported previously that in children with LCH, the BRAF V600E mutation was associated with high-risk disease features, permanent injury and poor short-term response to vinblastine-steroid induction therapy (H eritier et al, 2016 ).
In the current cohort of 48 children with BRAF V600E -mutated LCH, we found that positive detection of ccf BRAF V600E by picolitre droplet-based dPCR at diagnosis showed an even stronger association with severe clinical presentation at diagnosis, lower chemotherapy response and higher recurrence. Using the droplet-based dPCR assay, we demonstrated that mutated BRAF V600E ccfDNA could be detected in 100% of RO+ LCH children, and, less frequently, in ROÀ MS and SS LCH children (42% and 14%, respectively). ); ADB, recurrence after discontinuation, resumption of vemurafenib On vemurafenib therapy "-": Sample not available. 2CDA, cladribine; 6-MP, mercaptopurine; ADB, active disease better; ccf, circulating cell-free; LCH, Langerhans cell histiocytosis; MS ROÀ, multiple system LCH without risk organ involvement; MS RO+, multiple system LCH with risk organ involvement; NAD, non-active disease; NEG, negative; NR, non-responder; Se, threshold of sensitivity of detection (given for each negative sample); SS, single system LCH.
As reported previously with droplet-based dPCR assay (Chang-Hao Tsao et al, 2015) , most of the studied samples reached a threshold of sensitivity below 10
À3 . This threshold of sensitivity was lower than the mean ccf BRAF V600E load for RO+ MS children (2Á90%), indicating that droplet-based dPCR can be used to follow this biomarker and to correlate its levels with therapeutic response and changes in disease status (i.e. remission, recurrence) during the clinical course of this group of patients. For ROÀ LCH, because the ccf BRAF V600E load was often close to the threshold of sensitivity, the variations could only be interpreted in cases with persistent or higher positive quantification, as observed for the 2 children who experienced recurrence with RO involvement. This study confirmed the feasibility of using this method at the national level for patients with this rare disease (Guyot-Goubin et al, 2008) , especially for RO+ LCH children, who represent~15% of childhood LCH cases (Rigaud et al, 2016) . Plasma could easily be frozen at each institution (À80°C) and shipped to a centralized laboratory for testing with the droplet-based dPCR assay.
This non-invasive method should be considered in the context of other methods that can be used to follow the activity of LCH disease (Haupt et al, 2013) . In particular, it is important to consider how the results can be reliably interpreted and analysed for patient management. Conventional imaging, such as radiography and computed tomography scanning, are traditionally recommended for the initial (Haupt et al, 2013) and follow-up evaluation (Girschikofsky et al, 2013) of bone, soft tissue tumour and lung involvement. However, they are suboptimal for defining disease remission and for guiding decisions about therapy modifications, because lesions can appear to be stable for prolonged periods of time despite intralesional response. Anaemia, thrombocytopenia, and hypoalbuminaemia are usually present in RO+ LCH, and they may be relevant biomarkers of disease activity, but they are limited by their lack of specificity, especially after cytotoxic chemotherapy (Donadieu et al, 2015) . Thus, the droplet-based dPCR method could represent a way to blindly monitor independent markers of disease activity, and because of the very short half-life of ccfDNA (approximately 2 h) (Diaz & Bardelli, 2014) , this quantification offers almost real-time measurement.
Moreover, future clinical trials could use ccfDNA BRAF V600E , as detected by droplet-based dPCR, as a biomarker. Indeed, for 94Á4% of refractory RO+ MS LCH cases who were BRAF V600E -mutated (H eritier et al, 2016) , there is still no consensus regarding therapeutic management (Allen et al, 2015; Donadieu et al, 2015) , and the optimal strategy for using promising targeted therapies (H eritier et al, 2015) , like BRAF and MEK inhibitors, is not well established.
Others have reported the feasibility of detecting BRAF V600E ccfDNA in urine samples (Janku et al, 2014; Hyman et al, 2015) , which is an interesting option that merits further investigation. Alternatively Berres et al (2014) Our study highlights new interpretative parameters for understanding the natural history of LCH. Indeed, we observed that some patients treated by conventional chemotherapy and BRAF inhibitors who were considered to be responders remained positive for BRAF V600E . This may indicate that instead of quickly eradicating the disease, therapeutics slow down disease activity. This hypothesis is supported by the high recurrence rate in LCH, especially in BRAF V600E LCH (Berres et al, 2014) , which is estimated to be 43Á8% at 5 years (H eritier et al, 2016) . Thus, variation of the ccf BRAF V600E biomarker must be interpreted cautiously until the kinetics are evaluated in greater detail. We speculate that a ccf BRAF V600E load variation of more than 1 log 10 is needed for the result to be considered significant; otherwise, the patient should be tested for ccf BRAF V600E detection 1 or 2 months after the first test. As our study aimed to investigate the entire spectrum of LCH in children, our analysis was limited by the number of studied patients for each presentation of the disease. Our results showed that RO+ MS LCH children, as well as ROÀ LCH children who are non-responders to first-line chemotherapy, would benefit from the use of the ccf BRAF V600E biomarker. A large prospective study is needed to more accurately evaluate dynamic changes in the ccf BRAF V600E load in these two groups of patients.
